5-Amino-2,4,6-triiodoisophthalic acid

We are 5-Amino-2,4,6-triiodoisophthalic acid CAS:35453-19-1 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Product Name: 5-Amino-2,4,6-triiodoisophthalic acid
Synonym: 2,4,6-Triiodo-5-aminoisophthalic acid; ATIPA; Intermediate of Iohexol; Intermediate of Ioversol; Intermediate of Iopamidol
Cas No.: 35453-19-1
Formula: C8H4NO4I3
MW: 558.84
EINECS No.: 252-575-4

Density: 3.1±0.1 g/cm3
Boiling point: 539.4±50.0 °C at 760 mmHg
Melting point: 265-270 °C(lit.)
Flash point: 280.0±30.1 °C
Refractive index: 1.869

HS Code: 2942000000

UN No.: Not dangerous goods
 
Specification

Items of Analysis Standard of Analysis Test Results
Appearance Light yellow or off-white powder Conform
Purity (HPLC) ≥98.5% 99.69%
Melting Point 265-270℃ 266.6-268.3℃
Loss on drying ≤1.0% 0.47%
Any other individual impurity ≤0.5% Conform
Total sum of impurities ≤1.5% 0.31%
Conclusion Conforms to Factory Standard

 
 
Application
An important intermediate for nonionic iodinated X-ray contrast agents such as Iohexol, Ioversol and Iopamidol.
 
Packaging
25 kg/barrel, can also be packaged according to customer requirements. 
 
Storage
Store in a cool, ventilated warehouse. 
Keep away from fire and heat. 
The temperature should not exceed 37 °C. 

5-Amino-2,4,6-triiodoisophthalic acid


Related News: Any drug or medication is composed of two components.L-isoleucina CAS:73-32-5 The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.2,3-Di-O-para-toluoyl-D-tartaric acid The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.5-METILQUINOXALINA CAS:13708-12-8 The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
Glycylglycine View Details
2-(2-methyl-1H-indol-3-yl)ethanamine View Details
Methyltriacetoxysilane View Details
2-imidazol-1-ylacetic acid manufacturer 3-trimethoxysilylpropyl acetate manufacturer 2,4-Dichlorophenol manufacturer 4-(Hydroxymethyl)phenylboronic acid manufacturer ethyl 4-methoxy-3-oxobutanoate manufacturer